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Abstract
Lactococcus lactis is one of the most important microorganisms in the dairy industry and
has “generally recognized as safe” (GRAS) status. L. lactis belongs to the group of lactic
acid bacteria (LAB) and is encountered in a wide range of environments. Recently, the
use of the intramammary infusion of a live culture of LAB has been investigated as a new
antibiotic alternative for treating mastitis in dairy ruminants. Controversial results are
described in literature regarding its efficacy and safety. In this study we conducted in-
depth investigation of the mammary gland immune response induced by intramammary
inoculum of a live culture of L. lactis LMG 7930 using the mouse mastitis model. Overnight
cultures either of L. lactis ( 107 CFU) or of the mastitis pathogens Staphylococcus chro-
mogenes ( 105 CFU) or S. aureus ( 102 CFU/ml) were injected into the mouse inguinal
glands. A double injection, consisting of S. chromogenes first and then L. lactis, was also
investigated. Bacterial recovery from the gland and inflammatory cell infiltration were
assessed. L. lactis-treated and control glands were analysed for proinflammatory cytokine
production. Microbiological results showed that L. lactis was able to survive in the mam-
mary gland 24 h post infection, as were the mastitis pathogens S. chromogenes and S.
aureus. L. lactis reduced S. chromogenes survival in the glands and increased its own sur-
vival ability by coexisting with the pathogen. Histology showed that L. lactis-treated glands
presented variable histological features, ranging from undamaged tissue with no inflam-
matory cell infiltrate to severe PMN infiltrate with focal areas of tissue damage. S. aureus-
treated glands showed the most severe histological grade of inflammation despite the fact
that the inoculum size was the smallest. In contrast, most S. chromogenes-treated glands
showed normal structures with no infiltration or lesions. Significant increases in IL-1β and
TNF-α levels were also found in L. lactis-inoculated glands. The above findings seem to
suggest that food-grade L. lactis at a high-inoculum dose such as an overnight culture may
elicit a suppurative inflammatory response in the mammary gland, thus becoming a poten-
tial mastitis-causing pathogen. Because of the unpredictable potential of L. lactis in acting
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as a potential mastitis pathogen, this organism cannot be considered a safe treatment for
bovine mastitis.
Introduction
Mastitis, generally defined as the inflammation of the mammary gland, is one of the most prev-
alent diseases affecting dairy ruminants worldwide [1,2]. This disease causes huge economic
losses due to decreases in milk quantity and quality, veterinary services and labour expenses [3].
Antibiotics are extensively used for the treatment and prevention of mastitis in dairy rumi-
nants [4]. Due to concerns regarding the growing antibiotic resistance of mastitis-causing
pathogens that often make antibiotic therapy ineffective and the implications of the overuse of
antibiotics on public health, the development of alternatives are strongly encouraged.
The use of bacteriocins, such as nisin and lacticin 3147, has recently been proposed as an
alternative to antibiotics for treating and preventing bovine mastitis. The efficacy of bacterio-
cin-based formulations administered to the teat by dipping or intramammary infusion has
been documented both for treatment of clinical and subclinical bovine mastitis [5,6] and pre-
vention of streptococcal [7] and staphylococcal [8] mastitis infections in cattle. However, con-
troversial results are described in literature regarding the use of lactic acid bacteria (LAB) as
intramammary inocula for treating mastitis in dairy ruminants. On the one hand, safety and
efficacy in reducing Staphylococcus aureus infection have been described with the inoculation
of the live culture of Lactococcus lactis DPC 3147 [9]. On the other hand, inefficacy of the
intramammary Lactobacillus therapy in decreasing coagulase-negative staphylococci (CNS)
infections in cattle, has been documented [10]. Recently, our group has conducted in vitro
investigations of the probiotic potential of L. lactis subsp. lactis LMG 7930, a food-grade nisin-
producing strain, against mastitis-causing pathogens [11]. Our in vitro results suggested that
this strain might be a promising candidate for the development of new strategies of mastitis
control in ruminants [11]. We then discussed the efficacy and safety of the intramammary
infusion of an overnight culture of L. lactis LMG 7930 in in vivo studies under field conditions
(still unpublished data from our group). We conducted two trials involving naturally infected
ewes with clinical and subclinical staphylococcal mastitis. We found that the L. lactis treatment
rapidly activated the mammary glands’ innate immune response and initiated an inflamma-
tory response as evidenced by the recruitment of polymorphonuclear neutrophils (PMNs) and
increased somatic cell counts. But while leading to a transient clearance of CNS in the gland,
this response caused mild to moderate clinical cases of mastitis characterized by abnormal
milk secretions and udder inflammation (still unpublished data from our group).
To further investigate the host immune response induced by the intramammary infusion of
the L. lactis culture, we used the mouse mastitis model that is known to be more time- and
cost-effective than larger animal models. The experimental mouse model of mastitis was devel-
oped and characterized by Chandler in 1970 [12]. Although differences may exist between
ruminants and murine mammary glands [13], the mouse model of S. aureus mastitis provided
reliable, useful and economical alternatives for studying bacterial pathogenesis of bovine
mastitis-causing pathogens [14–17] and for primary evaluation of experimental drugs [18].
Recently, a mouse model of S. chromogenes mastitis has been proposed by Breyne and col-
leagues to study differences between bovine associated CNS species [19].
In this study, we have explored the effects of the intramammary inoculum of an overnight
culture of the food-grade L. lactis LMG 7930 strain on the mouse mammary gland immune
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response by proposing, for the first time, to the best of our knowledge, a mouse model of L. lac-
tis mastitis. Inoculum size, time of infection, bacterial recovery from the gland, histological fea-
tures and proinflammatory cytokine production are described.
Material and methods
Bacterial strains
L. lactis subsp. lactis LMG 7930 (BCCM/LMG Bacteria Collection, Belgium), a food grade
strain used in the dairy industry in the production of Swiss cheese, was used for the intramam-
mary inoculum. Two mastitis-causing pathogens, S. aureus LMG 16805 isolated from bovine
mastitis (BCCM/LMG Bacteria Collection, Belgium) and S. chromogenes 100-SA isolated from
a chronic case of subclinical mastitis in sheep (Istituto Zooprofilattico Sperimentale della Sar-
degna Bacteria Collection, Italy), were also used in this study.
Bacterial cultures were performed in Trypticase Soy Broth (TSB, BD, Italy) and incubated
at 37˚C for 24 h. Overnight cultures were used for the intramammary injection in mice. L. lac-
tis was used as is, while S. chromogenes and S. aureus were properly diluted in PSB to achieve
the desired concentration (see the “Mouse mastitis model of infection” section below). The
bacterial inoculum size was determined by serially diluting the culture and pour-plating the
dilutions on TSB agar.
Mice
A total of 41 timed-pregnant CD-1 mice (ca. 17 days of gestation), purchased from Envigo
RMS Srl (Italy), were considered. Mice were randomly divided into six groups: LL (n = 11,
treated with L. lactis), S.CH (n = 7, treated with S. chromogenes), S.CH-LL (n = 7, treated with
S. chromogenes and L. lactis), S.AU (n = 3, treated with S. aureus), PBS (n = 6, control group
treated with sterile PBS solution) and UNT (n = 7, untreated control group).
The animals were individually housed in the animal facilities of the Istituto Superiore di
Sanità (Rome, Italy). All procedures involving animals were approved by the Italian Ministry
of Health (Permit number 120/2014-B-24/03/2014). Animal care and treatment were con-
ducted in accordance with the institutional guidelines and international laws and policies
(Directive 2010/63/EU on the protection of animals used for scientific purposes).
Mouse mastitis model of infection
The general procedure for mouse mammary gland infection was adapted from the method
used by Breyne et al. [19] and Brouillette et al. [18]. Briefly, CD-1 lactating mice were used 10–
12 days after birth of the offspring. The pups were removed 2 h before inoculation into the teat
canal of the inguinal mammary glands L5 (on the left) and R5 (on the right). One hundred μl
of either an overnight culture of L. lactis (approximately 108 CFU/ml) or PBS-diluted cultures
of S. chromogenes (approximately 106 CFU/ml) and S. aureus (approximately 103 CFU/ml)
were used for the intramammary injections in groups LL, S.CH and S.AU, respectively. In the
S.CH-LL group, each gland received two consecutive injections: an initial inoculum of 100 μl
of S. chromogenes (approximately 106 CFU/ml) was followed by a second inoculum of 100 μl of
L. lactis (approximately 108 CFU/ml), 4 h later, in order to facilitate absorption. In the PBS
control group the inguinal glands were treated with 100 μl of PBS (Sigma Aldrich Srl, Italy).
Syringes with 33-gauge blunt needles were used for the inocula.
Twenty-four hours post infection (p.i.), all mice were sacrificed by cervical dislocation. For
each animal, both L5 and R5 mammary glands were aseptically collected and pooled for
A mouse mastitis model of Lactococcus lactis
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cultures and histological investigations. Cytokine production was also measured in the LL,
PBS and UNT groups.
Microbiological culture of mammary glands
Inguinal mammary gland samples from each animal were weighed, homogenized and cul-
tured. In summary, tissue samples were homogenized (1:1) in PBS and then serially diluted
(1:10). Dilutions were plated onto both Trypticase Soy Agar (TSA, BD, Italy)–nonselective
medium–and Mannitol Salt Agar (MSA, BD, Italy)–selective and differential medium used for
the isolation of pathogenic staphylococci–to enumerate bacteria. PBS and UNT control glands
were also plated onto both TSA and MRA. Plates were incubated for 24–48 h at 37˚C until col-
onies became visible for enumeration. In S.CH-LL, L. lactis counts were determined by sub-
tracting the total S. chromogenes + L. lactis obtained on TSA from the S. chromogens counts
obtained on MSA.
Random colonies were picked from each plate and molecularly identified by PCR amplify-
ing and sequencing 16S rDNA [20]. Results were expressed as colony forming unit per gram
(CFU/g) of mammary gland. Mean values per group with standard deviation were then
calculated.
Histological investigation
Mammary gland samples from all groups were fixed in 10% neutral buffered formalin and rou-
tinely processed to obtain 4 μm paraffin-embedded histological sections which were then
stained with haematoxylin and eosin and examined via light microscopy.
Lesions observed were measured semiquantitatively using a scoring system based on the
characterization of the inflammatory cell infiltrate, specifically by accumulation of PMNs,
according to the literature [21]. A scale from 1 to 4 was applied to the following alterations: 0,
no lesions, absence of interstitial and/or alveolar inflammatory cell infiltrate and undamaged
tissue; 1, focal to multifocal, mild interstitial and/or alveolar infiltrate of inflammatory cells
and undamaged tissue; 2, multifocal, moderate interstitial and/or alveolar infiltrate of inflam-
matory cells and undamaged tissue; 3, severe, diffuse interstitial and/or alveolar infiltrate of
inflammatory cells and focal areas of tissue damage; 4, severe, diffuse interstitial and/or alveo-
lar infiltrate of inflammatory cells and extensive necrotic areas. All the slides were assessed
blinded by three observers (EB, LS and MTC) using a light microscope, and the discordant
cases were reviewed at a multi-head microscope until a consensus was reached.
Cytokine analysis
Mammary gland samples from the LL, PBS and UNT groups were weighed and homogenized
in PBS (1: 9, w/v) supplemented with a cocktail of protease inhibitors which is able to inhibit
serine and cysteine proteases, calpain proteases and metallo-proteases (Roche, Germany). The
homogenate was centrifuged at 2000 x g for 30 min at 4˚C, and the supernatant was collected.
The levels of the cytokines interleukin (IL)-1β and tumour necrosis factor (TNF)-α were deter-
mined by using an ELISA kit (PeproTech, Germany), according to the manufacturer’s instruc-
tions and the literature [22]. ELISA tests were performed in triplicate. Mean values per group
with standard deviation were then calculated.
Statistical analysis
Mean values per group with standard deviation were used to describe data sets of bacterial
recovery and cytokine production.
A mouse mastitis model of Lactococcus lactis
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Two-way ANOVA was performed to analyse main effects of L. lactis and S. chromogenes
inoculations, as well as their interaction. Post-hoc Tukey’s multiple comparisons test was per-
formed where appropriate.
Inter-group analyses of differences in TNF-α and IL-1β levels among LL, PBS and UNT
were performed by the one-way ANOVA, followed by Tukey’s multiple comparisons test
where applicable.
GraphPad Prism 6 version 6.07 for Windows, GraphPad Software, La Jolla California USA,
www.graphpad.com, was used. Differences were considered significant at P< 0.05.
Results
Recovery of bacteria from glands
Bacterial count mean values of L. lactis (groups LL and S.CH-LL), S. chromogenes (groups S.
CH and S.CH-LL) and S. aureus (S.AU group) are shown in Fig 1 and expressed as log10 CFU/
g of gland.
All bacteria here tested were recovered from the glands at 24 h p.i. The mean value of S.
aureus count in S.AU (1.79 x 108 CFU/g of gland) was greater than the mean values recorded
for L. lactis in LL (9.32 x 106 CFU/g of gland) and S.CH-LL (5.78 x 107 CFU/g of gland) and
for S. chromogenes in S.CH (1.55 x 103 CFU/g of gland) and S.CH-LL (2.56 x 102 CFU/g of
Fig 1. L. lactis, S. chromogenes and S. aureus counts. All inoculated bacteria were counted in mammary glands at 24 h p.i. in treated
(LL, S.CH, S.CH-LL, S.AU and PBS) and untreated (UNT) groups. Results are expressed as mean values with standard deviation of log10
CFU/g values. The initial bacterial inoculum size is shown. Significant differences are indicated. * P 0.05, ** P 0.01.
https://doi.org/10.1371/journal.pone.0184218.g001
A mouse mastitis model of Lactococcus lactis
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gland) even though the inoculum size of S. aureus was smaller than that of L. lactis or S. chro-
mogenes. Main effects of S. chromogenes (F = 6.80, P = 0.0147), L. lactis (F = 13.03, P = 0.0012)
as well as their interaction (F = 6.80, P = 0.0147) were observed on L. lactis counts. A signifi-
cant increase of L. lactis recovery was found in S.CH-LL compared to LL (P = 0.0025). Main
effects of S. chromogenes (F = 8.50, P = 0.0071), L. lactis (F = 4.36, P = 0.0464) and their interac-
tion (F = 4.36, P = 0.0464) were also observed on S. chromogenes counts. A significantly lower
bacteria recovery was recorded in S.CH-LL mice compared to the S.CH group (P = 0.0364).
No bacterial colonization was observed in the control glands (groups PBS and UNT).
Histopathological changes
Representative histological sections, scored from 0 to 4, are shown in Fig 2. Most of the mam-
mary gland tissue samples from the PBS (4/6) and UNT (5/7) groups, as well as from S.CH (6/
7), showed a normal structure and no infiltration or lesions (score 0), as shown in panel A.
The rest showed minimal interstitial non suppurative inflammations (score 1): 2/6 in PBS, 2/7
in UNT and 1/6 in S.CH.
The glands challenged with L. lactis (LL and S.CH-LL) showed variable histological features,
with scores ranging from 0 to 3. In LL, tissue damage recorded ranged from no lesions (3/11,
score 0) to mild (1/11), moderate (5/11) and severe (2/11) inflammatory cell infiltrations,
scored from 1 to 3, respectively (panels B-D). In S.CH-LL, no lesions (1/7, score 0), as well as
Fig 2. Histological changes in the murine mammary glands. Panels A: UNT group, score 0, no infiltration and undamaged tissue; B: LL
group, score 1, mild PMN infiltration in isolated areas of tissue sections; C: LL group, score 2, moderate PMN alveolar and interstitial
infiltration; D: LL group, score 3, severe PMN infiltration and focal areas of tissue damage; E: S.AU group, score 4, severe PMN infiltration
and extensive necrotic areas. Magnifications 20X, bar = 100 μm.
https://doi.org/10.1371/journal.pone.0184218.g002
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mild (2/7, score 1) and severe inflammatory cell infiltrations (4/7, score 3) were histologically
documented. In S.AU, the S. aureus challenge caused severe PMN infiltrations with extensive
necrotic areas (3/3, score 4) in the mammary glands (panel E).
Effect of L. lactis on the proinflammatory cytokine production
TNF-α and IL-1β levels were measured in L. lactis-treated (LL), PBS-treated (PBS) and
untreated (UNT) control glands at 24 h p.i. and expressed as mean values with standard devia-
tions (pg/ml) in Table 1.
Significant differences in the proinflammatory cytokine production data set were observed
comparing LL versus UNT only. Significant increases in TNF-α (P = 0.0351) and lL-1β
(P = 0.0204) levels were recorded in LL. Comparing LL versus PBS data sets, no statistical dif-
ferences were found, although higher levels of TNF-α and IL-1β were recorded in LL. Higher
levels of TNF-α and IL-1β were recorded in two L. lactis-treated glands presenting severe
PMN infiltrations at histology. The more pronounced dispersion was observed in IL-1β values
in LL as measured by the standard deviation. Results as shown in Table 1.
Discussion
We have previously assessed, in two trials, the efficacy and safety of intramammary infusion of
a live overnight culture of the food-grade Lactococcus lactis LMG 7930 for the treatment of sub-
clinical (by CNS infections) and clinical (by S. aureus infections) mastitis in lactating ewes. We
have found that, under our experimental conditions, the live bacterial culture rapidly activated
the mammary innate immune system. This led to a transient clearance of the CNS in the
gland, but also caused mild to moderate clinical cases of mastitis (still unpublished data from
our group). To make further progress in our understanding of L. lactis mastitis, we decided to
study the interaction between L. lactis LMG 7930 and the mammary gland in a mouse mastitis
model in greater detail.
The mouse mastitis model has been proven to be a fast, cheap and reproducible intermedi-
ate in vivo alternative for studying the specific host immune response to intramammary injec-
tion with major mastitis pathogens, such as Escherichia coli and S. aureus [15,23]. Recently, a
pilot study has suggested that a mouse mastitis CNS model can mimic bovine CNS mastitis
and be used to study differences between bovine CNS species and strains [19]. Here we investi-
gated whether an intraductal injection of an overnight L. lactis culture into the murine mam-
mary gland (approximately 107 CFU/100 μl) can be used to evaluate L. lactis survival in the
tissue and success in overcoming host immune response 24 h p.i. Therefore we conducted
microbial cultures and histopathological investigations on L.lactis-treated mammary glands.
We also treated additional mice with bacterial suspensions of mastitis-causing pathogens, i.e.
S. chromogenes (S.CH) or S. aureus (S.AU) in order to have two mouse mastitis models as com-
plementary tools to better evaluate the effects of the L. lactis challenge into the mammary
gland. We decided to inoculate approximately 105 CFU/100 μl of S. chromogenes because a
Table 1. Proinflammatory cytokine production in the LL, PBS and UNT groups.
Cytokine (pg/ml) LL PBS UNT Significant difference
TNF-α 267 ± 83 165 ± 49 142 ± 62 LL vs UNTP = 0.0351
IL-1β 5383 ± 1007 4117 ± 300 3762 ± 534 LL vs UNTP = 0.0204
Results are expressed as mean values with standard deviation. Differences in TNF-α and IL-1β levels among LL, PBS and UNT were determined by the
one-way ANOVA, followed by Tukey’s multiple comparisons test where applicable. Significant differences (P<0.05) are shown.
https://doi.org/10.1371/journal.pone.0184218.t001
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previous study had documented that an S. chromogenes inoculum dose as high as 105 CFU dis-
played clinical symptoms of inflammation if inoculated into murine mammary glands [19].
According to the validated mouse mastitis S. aureus model, we inoculated approximately 102
CFU/100 μl of S. aureus because an inoculum dose as high as 100 CFU of that pathogen has
been proven to be nonfatal and to cause a significant level of infection with evident signs of
mammary gland inflammation at 24 h p.i. [18,19]. An additional group was included in our
study: S.CH-LL, containing animals treated with two separate injections–S. chromogenes first,
followed by L. lactis–in order to assess whether L. lactis was able to affect S. chromogenes sur-
vival in the mammary gland.
Microbiological results showed that L. lactis was able to survive in the mammary gland 24 h
p.i., as were the mastitis pathogens S. chromogenes and S. aureus. In contrast, no bacterial colo-
nization was observed in the control glands (groups PBS and UNT). We observed that L. lactis
reduced S. chromogenes survival in the glands in S.CH-LL at 24 h p.i., and increased its own
survival ability by coexisting with the pathogen. It seems that L. lactis and S. chromogenes
engaged in interspecies cooperative behaviours rather than competitive interactions. Bacterial
species may in fact coexist with, or dominate, other organisms, competing for the same pool of
resources by adopting many active mechanisms [24]. L. lactis-treated glands showed variable
histological features, ranging from undamaged tissue with no inflammatory cell infiltrate to
severe PMN infiltrate with focal areas of tissue damage (scores 0 to 3). A moderate mammary
gland inflammation characterized by alveolar and/or interstitial PMN infiltration was the most
prevalent change observed in the mammary glands challenged with L. lactis alone (LL). Glands
challenged with both S. chromogenes and L. lactis (S.CH-LL), however, showed a more severe
degree of inflammation. Neutrophil infiltration was observed in almost all glands and in both
interstitium and alveoli, suggesting a more severe inflammation than observed in udders chal-
lenged with L. lactis alone. These differences in histology are likely related to the greater num-
ber of L. lactis colonies measured in S.CH-LL than that recorded in LL.
Proinflammatory cytokine production was measured in LL, PBS and UNT glands. Signifi-
cant increases in IL-1β and TNF-α levels were found in L. lactis-inoculated glands by compar-
ing LL with UNT. However, no significant changes were observed between groups LL and
PBS, although we recorded higher proinflammatory cytokine trends and a more pronounced
dispersion of values in LL. The cytokine production results are in accordance with the greater
number of glands with inflammatory cells infiltrate that we recorded in LL compared with the
control groups.
Predictably, bacterial growth in S. aureus inoculated glands was the highest we recorded,
even though the inoculum size was the smallest. Moreover, S. aureus-treated glands all showed
the most severe histological grade of inflammation (score 4). Both results are compatible with
previous studies [18,19] and seem to support an inoculum dose as high as 100 CFU of a masti-
tis S. aureus isolate per gland, irrespective of the strain, like the injection that was able to cause
severe mammary gland inflammation in the mouse model at 24 h p.i. That confirms lactating
mice as animals very susceptible to intramammary infusion by S. aureus. Contrary to our
expectations, the mastitis isolate of S. chromogenes here used was unable to induce mastitis
when it was used alone at the inoculum size as high as 105 CFU at 24 h p.i. Indeed, most mam-
mary glands in S.CH showed normal structures with no inflammatory infiltration or lesions
detected by the histological exam. Concordant results were found in the control groups (PBS
and UNT). Few cases of mammary gland inflammation–and, moreover, mild ones–were
recorded in S.CH, as well as in PBS and UNT. That mild inflammation seemed to have been
caused by milk accumulation (physiological inflammation) rather than by the pathogen or
inoculum itself. The rapid accumulation of milk in the mammary gland–due to the permanent
removal of offspring from a lactating mother, which is referred to in the literature as “forced
A mouse mastitis model of Lactococcus lactis
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weaning”–has been documented to result in elevation of inflammatory mediators [25] and
influx of macrophages into the mammary gland [26,27], all of which are critical components
of the cell death and tissue remodelling process [28]. Our results together with the literature
[19] confirm that CNSs are minor mastitis pathogens and that epidemiologically different
mastitis isolates of CNS strains may induce variable host innate immune responses in the
mouse mammary gland.
In conclusion, the L. lactis inoculum caused variable histological features in the mammary
gland, ranging from undamaged tissue to severe inflammation. Our results suggest that bacte-
ria with GRAS status, such as L. lactis, can act as mastitis-causing pathogens when inoculated
at high density into the mammary glands of lactating mice. Because of the unpredictable
potential of L. lactis in acting as a potential mastitis pathogen, this organism cannot be consid-
ered a safe treatment for bovine mastitis.
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